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ABSTRACT
Increased cell proliferation is a central key event in the mode of action for many non-genotoxic carcinogens, and quantitative cell proliferation
data play an important role in the cancer risk assessment of many pharmaceutical and environmental compounds. Currently, there is limited unified
information on assay standards, reference values, targeted applications, study design issues, and quality control considerations for proliferation data.
Here, we review issues in measuring cell proliferation indices, considerations for targeted studies, and applications within current risk assessment
frameworks. As the regulatory environment moves toward more prospective evaluations based on quantitative pathway-based models, standardization of proliferation assays will become an increasingly important part of cancer risk assessment. To help address this development, we also discuss
the potential role for proliferation data as a component of alternative carcinogenicity testing models. This information should improve consistency of
cell proliferation methods and increase efficiency of targeted testing strategies.
Keywords:
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proliferation play a key role in clinical characterization of different human cancers, including tumor grade, response to therapy, and prognosis (Dowsett et al. 2011; Sestak et al. 2013),
and specific pathways involved in cell proliferation serve as
important targets for a large number of anticancer therapeutics
(Hudis 2007; Cataldo et al. 2011).
Cancer may be defined as poorly controlled cellular
growth arising from errors in DNA. Typically, multiple
(uncorrected) errors in a single cell are required in critical
portions of specific oncogenes or tumor suppressor genes for

Carcinogenesis is now recognized as a multistep process in
which normal cells progressively acquire a set of core traits that
facilitate and ultimately characterize a malignant state (Hanahan and Weinberg 2000, 2011). Of these features, perhaps the
most fundamental is a sustained proliferative signal. Disruption
in normal cell proliferation is considered to be a common early
event in the natural history of cancer and a requirement for progression of a normal cell through the various steps to malignancy. This basic process drives the selection, growth, and
eventual autonomy of neoplastic cells. Biomarkers related to
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progression to malignancy. Although DNA replication is
highly precise in most cell types, spontaneous errors occur
every time DNA is copied. These errors are the result of processes or alterations that occur in the DNA of all cells, including oxidative damage, deamination, and adduct formation
(Ames and Gold 1990; Swenberg et al. 2011). The number
of replication errors varies with cell type, and increasing evidence indicates that for such mistakes to result in cancer, they
must occur in progenitor/stem cells of the target tissue (Knudson
1971; Moolgavkar and Knudson 1981; Greenfield, Ellwein, and
Cohen 1984; Flesken-Nikitin et al. 2013; Tomasetti and Vogelstein 2015). When errors do occur, they are permanently fixed
during DNA replication in the S phase of the cell cycle. Based
on these principles, an agent can increase the risk of cancer by
directly inducing DNA damage (DNA reactive), by indirectly
promoting errors through increased DNA replication (proliferative), or by a combination of these events (Knudson 1971; Moolgavkar and Knudson 1981; Greenfield, Ellwein, and Cohen
1984; Cohen and Ellwein 1990, 1991). Increased cell division
may thus drive clonal expansion of cells with prior DNA damage, increase the number of target cells for DNA-damaging
agents, or increase the probability of spontaneous genetic errors
(Preston-Martin et al. 1990; EPA 2005).
At a basic level, increased cell proliferation occurs by an
increase in cell births and/or a decrease in cell deaths (Moolgavkar and Knudson 1981; Cohen 1995). An increase in cell
births can occur either by mitogenicity resulting from hormonal
or growth factor signals or by cytotoxicity followed by regeneration. Direct mitogenicity usually involves interactions with
specific cellular receptors, while cytotoxicity usually involves
necrosis, apoptosis, and/or inflammation, which can result in
local signals leading to regenerative proliferation (Pastoor
et al. 2005; Dragan et al. 2001). Other less common mechanisms of increased cell proliferation include removal or inhibition of suppressive growth signals, resulting in indirect
mitogenesis. A decrease in cell death can occur by inhibiting
apoptosis or cell differentiation, which can lead to an accumulation of target cells even if the rate of cell proliferation
remains the same. Alternatively, greater proliferation at an
early point in time may have an amplifying effect on cell number later in life (Ellwein and Cohen 1990). In such cases, the
number of cell replications, rather than the replication rate, may
be a key parameter in evaluating overall proliferative activity.
Given the important role of cell proliferation in carcinogenesis, quantitative proliferation markers are now widely used in
cancer risk assessment of pharmaceutical and environmental
compounds. When tumor outcomes have been identified in animals, cell proliferation data are often an important part of the
carcinogenic mode of action (MOA), which characterizes the
requisite key events and/or processes leading to the observed
tumor (Sonich-Mullin et al. 2001; Meek et al. 2003; Boobis
et al. 2006; Meek et al. 2014). For non-genotoxic carcinogens,
these key events often include an increase in proliferation of
the target cell population. Increasingly, proliferation data are
also being incorporated into predictive or prioritization models
of chemical agents with unknown carcinogenic potential
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(Cohen 2004, 2010; Sistare et al. 2011). In such models, identifying true risk signals associated with cancer risk will be an
important challenge in the future requiring greater data
consistency.
The goal of this article is to present unified information
related to the generation, interpretation, and use of proliferation
data. Although our focus here is carcinogenesis, many of the
concepts covered are applicable to other areas of safety assessment. We will review standard methods for measuring cell proliferation in tissue sections and address common sources of
technical and analytical variability. We will also present design
considerations for targeted studies and discuss the use of cell
proliferation data within current risk assessment frameworks.
Finally, we will discuss the potential role for proliferation data
in proposed alternative carcinogenicity testing models and the
importance of standardization in these efforts.
IMMUNOHISTOCHEMICAL MARKERS

FOR

CELL PROLIFERATION

Commonly used methods for quantifying cell proliferation
in fixed tissue sections are based on chromogenic labeling by
immunohistochemistry (IHC). The most common markers are
5-bromo-20 -deoxyuridine (BrdU), Ki-67 (syn. Ki-67, MKi67), and proliferating cell nuclear antigen (PCNA). Other less
commonly used proliferation markers detected by IHC (e.g.,
phospho-histone H3), in situ hybridization (e.g., histone messenger RNA), and fluorescence microscopy (e.g., 20 -deoxy-5ethynyluridine [EdU]) are not discussed here. Rather, our focus
will be on cell labeling index (LI) for BrdU, Ki-67, or PCNA as
a common metric for cell proliferation data. As we will discuss,
these markers identify cells actively moving through the cell
cycle. Their primary use is in assessing changes in proliferation
LI within a population of target cells during a specific window
of time. While increased LIs may in some cases correspond to
preneoplastic or neoplastic changes, these markers do not specifically identify dysregulated or aberrant proliferation at the
level of an individual cell.
The original in situ measure for proliferating cells in
formalin-fixed paraffin-embedded (FFPE) sections was the
mitotic index, determined by counting the number of mitotic
figures within a given field or population of cells. While technically simple, this approach is often impractical in studies of
nonneoplastic tissues with low proliferation rates such as liver,
kidney, urinary bladder, or mammary gland. The mitotic phase
of the cell cycle can be up to 10 times shorter than the S phase
(Alberts et al. 2007), leading to low counts per field in many
tissues and requiring extensive and laborious counting. To
improve sensitivity and reduce the number of cells required
to count, tritiated (3H)-thymidine methods were developed
(Hughes et al. 1958). When combined with autoradiography,
this method was the first to allow microscopic counting of cells
that had entered the S phase of the cell cycle (Figure 1A). The
main disadvantages of this method were the use of radioactive
materials and the long duration needed for autoradiography (>2
weeks). In the early 1980s, IHC staining using antibodies to
the synthetic thymidine analog BrdU was introduced as an
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FIGURE 1.—Markers of cell proliferation. (A) Tritiated thymidine labeling of mouse hepatocytes. Note dark granules indicating radiolabeled thymidine molecules. Hematoxylin and eosin (H&E) background stain, 40 objective magnification. (B) 5-bromo-20 -deoxyuridine (BrdU) labeling
of rat colonic crypt epithelial cells. Hematoxylin background stain, diaminobenzidine (DAB) chromogen, 40 objective magnification. (C, D)
Images of Ki-67-labeled mouse hepatocytes before (C) and after (D) automated cell selection. In this example, cells were sorted and colorcoded by nuclear shape, size, and label. Hematoxylin background stain, DAB chromogen, 10 objective magnification.

alternative approach for measuring S phase cells without
radioisotopes or autoradiography (Gratzner 1982). Immunostaining for BrdU was faster (1–2 days) and provided better
visualization of cells in sections (Figure 1B). These advantages led to widespread adoption of BrdU by the early
1990s as the standard for measuring proliferation LI, particularly in toxicological studies (Leif, Stein, and Zucker 2004).
The major disadvantage of BrdU is the requirement for inlife labeling, typically by injection or surgical placement of
osmotic pumps, which precludes in situ detection of BrdU
in human tissues and archival nonclinical specimens without
prior BrdU exposure.
To address these limitations, monoclonal antibodies (mAbs)
to PCNA and Ki-67 were developed concurrently in the 1980s
for immunolabeling of proliferating cells without in-life treatment (Gerdes et al. 1983; Figure 1C–D). PCNA is a nonhistone
nuclear protein that acts as a sliding DNA clamp during DNA
replication (Paunesku et al. 2001), while Ki-67 is thought to
function in ribosomal RNA transcription (Bullwinkel et al.
2006). In contrast to BrdU, PCNA and Ki-67 proteins are
expressed by cells in G1, S, G2, and M phases of the cell cycle
but not the G0 phase and thus more accurately measure the

growth fraction (or proliferative ‘‘state’’) of a cell population
(Kurki et al. 1986; Scholzen and Gerdes 2000). Maximal
PCNA expression occurs in the late G1 and S phases (Scholzen
and Gerdes 2000), while Ki-67 levels are low during G1 and
early S phases and progressively increase from mid-S phase
until late M phase, when levels rapidly decline (Lopez et al.
1991; Figure 2A). These 2 markers label virtually all known
cell types across a wide variety of species, allowing for
cross-species comparisons. Expression across multiple stages
of the cell cycle also provides greater dynamic range in LIs
compared to mitotic counts, which may be zero or near zero
in many nonneoplastic tissues.
Early use of PCNA and Ki-67 favored PCNA mainly
because the primary antibody to PCNA (PC10) could be used
on both frozen and FFPE sections, while the original Ki-67
antibody was limited to frozen sections only. This situation
changed with the development of MIB-1 and other Ki-67 mAbs
in the 1990s that could be used on both frozen and FFPE sections (McCormick et al. 1993). Other evidence showed sensitivity of PC10 to fixation and heat-induced antigen retrieval
(AR) methods and potential functions of PCNA distinct from
cell proliferation (Tahan et al. 1995; Prosperi 1997; Scholzen
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FIGURE 2.—Patterns of expression for different cell proliferation markers. (A) labeling dynamics for 5-bromo-20 -deoxyuridine (BrdU), proliferating cell nuclear antigen (PCNA), and Ki-67 across the cell cycle.
Note that these are general patterns that may vary based on cell type.
Broken lines indicate potential die-off (for BrdU) and persistence (for
PCNA). (B) Labeling dynamics for different proliferative responses
over time. Classic patterns include plateau mitogens (e.g., ERa agonists > uterus), burst mitogens (e.g., PPARa agonists > liver), and
regenerative proliferation following cytotoxicity (e.g., chloroform >
kidney), which may appear at acute to chronic time points.

and Gerdes 2000), leading to greater use of Ki-67 in human
cancer research and other fields.
Numerous human and rodent studies have shown significant
correlation among BrdU, PCNA, and Ki-67 LIs (Goodson et al.
1998; Thor et al. 1999; Birner et al. 2001; Urruticoechea,
Smith, and Dowsett 2005; Dowsett et al. 2011). Marker LIs
also tend to correlate well with mitotic index in samples with
high enough proliferation rates to get meaningful mitotic
counts, mainly tumor studies (Thor et al. 1999). Notable inconsistencies between markers have also been reported. Such differences may relate to variations in fixative, antibody, IHC
protocol, tissue type, duration of BrdU exposure, and treatment
conditions, as discussed subsequently (Holt et al. 1997; Tanaka
et al. 2011). In general, Ki-67 labeling appears to correlate
more strongly with BrdU than with PCNA in most tissues
(Urruticoechea, Smith, and Dowsett 2005; Dowsett et al.
2011), while PCNA shows variable correlation with Ki-67 or
BrdU (Muskhelishvili et al. 2003; Eldridge and Goldsworthy
1996).
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The relative magnitude of LIs also varies by marker. For
example, BrdU is higher than Ki-67 in some studies but lower
in others, likely as a function of proliferation rate and in-life
BrdU treatment time (Birner et al. 2001; Muskhelishvili et al.
2003). When measured together, LIs for PCNA tend to be higher
than Ki-67 (Muskhelishvili et al. 2003), perhaps due to the nonproliferation functions of PCNA (Prosperi 1997; Pauneska et al.
2001) or longer half-life for PCNA (~20 hr) compared to Ki-67
(1–2 hr; Bravo and Macdonald-Bravo 1987; Bruno and Darzynkiewicz 1992). Importantly, cell labeling for BrdU increases
with in-life BrdU exposure because all cells passing through the
S phase of the cell cycle retain BrdU. As an example, a recent
study reported BrdU LIs of 6%, 12%, and 23% in the terminal
bronchiolar cells of mice after 1, 2, and 4 weeks of continuous
BrdU infusion, respectively (Kameyama et al. 2014). In contrast,
Ki-67 and PCNA evaluate a more discrete window of proliferative activity at the time of sample collection. Features of BrdU,
Ki-67, and PCNA markers are summarized in Table 1.
Antibodies to BrdU, PCNA, and Ki-67 are commercially
available for IHC in all standard research species. Anti-BrdU
mAbs are most diverse (Liboska et al. 2012); common clones
include BU20a in mouse and BU-1/75 in rat, but there is wide
variation in anti-BrdU antibodies across studies. For PCNA, the
PC10 clone mouse mAb is most widely used and cross-reacts
with most species tested; however, other clones may be preferred
for mouse tissues to avoid background staining due to nonspecific binding to endogenous immunoglobulins. For Ki-67, the
MIB-1 antibody widely used for human tissues cross-reacts with
the Ki-67 protein in many nonhuman species (e.g., monkey, dog,
ox, horse, sheep) but not rodents (Birner et al. 2001), for which
other clones are available (e.g., MIB-5 and SP6).
VARIABILITY

IN

METHODS

FOR

MEASURING CELL PROLIFERATION

Consistency between laboratories and studies is an important issue in evaluating cell proliferation data (Dowsett et al.
2011; Polley et al. 2013; Nolte et al. 2005). Most laboratories
rely upon indirect IHC methods with primary and secondary
antibodies, horseradish peroxidase– or alkaline phosphatase–
conjugated streptavidin labels, commercial chromogens such
as diaminobenzidine (DAB), and counterstaining with hematoxylin. Beyond these standard procedures, there may be
important differences across laboratories related to sample
fixation, tissue processing and storage, marker and antibody
selection, IHC equipment, and other technical details of IHC
protocols. Such differences may impact LI readouts. Several
work groups have been formed to address this issue for clinical
applications related to the Ki-67 marker (Dowsett et al. 2011;
Polley et al. 2013). Similar efforts exist for preclinical applications as well, although to date these have been more limited
(Nolte et al. 2005). In this section, we will briefly consider
pre-analytical sources of variation in LI data.
Sample Preparation
Tissue collection should be one of the initial considerations
for any cell proliferation study. Sampling protocols will vary
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TABLE 1.—Summary features for different immunohistochemical proliferation markers.
Feature

BrdU

Cellular localization Nuclear
Label dynamics
Incorporated in S phase
Label duration
Persistent
Considerations
 In-life exposure
 Direct effects
 DNA denaturation step
required

PCNA
Nuclear
Expressed in non-G0 phases (peak in late G1/S)
Transient (*20 hr half-life)
 Expression window
 Nonspecific expression (e.g., DNA repair)
 greater sensitivity to fixative effects

Ki-67
Nuclear
Expressed in non-G0 phases (peak in late S/M)
Transient (1–2 hr half-life)
 Expression window
 Less sensitive to fixation
 Cell cycle dynamics (e.g., arrest)
 Cross-species use
 Cross-species use

Note: BrdU ¼ 5-bromo-20 -deoxyuridine; PCNA ¼ proliferating cell nuclear antigen.

by experiment and tissue type but should be clearly defined
prior to necropsy to ensure consistency and alignment with
study goals. A technically detailed collection and trimming
protocol will aid in the identification of the same macroscopic
region for each target tissue and increase concordance between
target site and proliferation measurements. For example, if
nasal epithelial tumors were observed in a carcinogenicity
study within a specific region of the nasal turbinates, then it
is critical to analyze this region in the corresponding shorterterm proliferation study and not an arbitrary region of the nasal
cavity. If mass lesions are observed in the target tissue, these
should be collected separately from grossly normal tissues to
avoid a mixed batch of neoplastic and nonneoplastic samples
resulting in missing or biased data. Cell proliferation LIs from
proliferative lesions (e.g., hyperplastic focus or tumor) should
generally be excluded or analyzed separately from morphologically normal areas.
Tissue fixation is another variable to consider in cell proliferation studies. The most widely used fixative for histology is
formalin, which preserves tissue architecture mainly by crosslinking proteins. These cross-links may mask antigens and
thereby interfere with IHC labeling (Puchtler and Meloan
1985). Prior studies have consistently shown that formalin fixation for prolonged periods (typically >24 hr) may decrease
BrdU LIs compared to matched frozen samples (McGinley,
Knott, and Thompson 2000). Similar or greater effects have
been reported for PCNA LIs (Tahan et al. 1995; Casasco
et al. 1994). Labeling for Ki-67 (MIB-1 at least) has generally
shown more resistance to formalin fixation effects compared to
BrdU and PCNA, but loss of antigenicity may still occur
(McCormick et al. 1993; Hendricks and Wilkinson 1994;
Benini et al. 1997; Holt et al. 1997; Arber 2002; Otaliet al.
2013). These observations have led to the practice of fixing tissues for IHC initially in 10% buffered formalin (or fresh 4%
paraformaldehyde) for 12 to 24 hr and then transferring them
to 70% ethanol or alternative alcohol-based fixatives that do
not form protein cross-links (McGinley, Knott, and Thompson
2000; Otali et al. 2013). In some instances, fixation directly in
70% ethanol may be optimal (Ohnishi et al. 2007), depending
on the specific requirements of the antibodies used. Ideally,
internal optimization and validation of fixation protocols
should be documented in the operating procedures for each
laboratory. Use of a positive proliferation control reference

group (e.g., treated with a known mitogen for the tissue of
interest) will also help distinguish true negative results from
signal loss related to fixation, especially for studies in which
low control LIs are expected.
The length of time FFPE tissues stay in paraffin block (or
sectioned on slide) prior to IHC staining can also affect antigenicity for proliferation markers. Age-in-block is an important
consideration when using archived samples that differ in age
(e.g., tumor case series) or performing a retrospective analysis
of tissue samples from an older study (Greenwell, Foley, and
Maronpot 1993). Prolonged age-in-block can lead to variable
or tissue-specific loss of antigenicity depending on storage conditions and prior tissue processing (Karlsson and Karlsson
2011; Xie et al. 2011). For archival case studies or crossstudy comparisons, it is important to include fixation method
and age-in-block as covariates in the analysis.
Immunolabeling
Potential differences in IHC procedures across laboratories
include the use of automated compared to manual slide staining, primary antibody dilution, buffer selection, and incubation
times (Nolte et al. 2005). Given this variability, it is critical that
internal optimization and validation of IHC protocols are used
to determine the most appropriate staining conditions (Hendricks and Wilkinson 1994). Reporting full details of these
methods will also facilitate greater concordance between studies and laboratories and aid in interpretation of unexpected or
marginal treatment effects.
General recommendations for IHC quality control include
negative and positive staining control slides run for each staining batch. For negative control slides, nonimmune serum from
the same species as the primary antibody is often applied in
place of the primary antibody. For positive controls, a tissue
with high basal proliferation (e.g., intestine, stomach, or lymph
node) from the same animal or study may be run in each batch
or on each slide to confirm appropriate label administration (for
BrdU) and staining. Non-target cells with proliferative activity
(e.g., lymphocytes) may also serve as internal positive controls
for some tissues. For new mAb clones or lots, a dilution series
is recommended to account for any shifts in affinity.
Epitopes masked by fixative cross-links, FFPE processing,
and age-in-block effects can be partially recovered through
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various AR methods (D’Amico, Skarmoutsou, and Stivala 2009;
Shi, Key, and Kalra 1991; Greenwell, Foley, and Maronpot
1993). While critical to many IHC protocols, the degree of epitope recovery often varies (McGinley, Knott, and Thompson
2000). The most common AR method is heating via microwave,
water bath, or steamer, often with a citrate buffer; alternative
techniques include use of proteolytic enzymes or other chemical
treatments (D’Amico, Skarmoutsou, and Stivala 2009). Importantly, both heat and chemical AR methods may potentially
increase background labeling (D’Amico, Skarmoutsou, and Stivala 2009; Bak and Panos 1997). General recommendations to
minimize this nonspecific labeling include avoidance of extreme
AR conditions (e.g., heat and pH), inclusion of control conditions for endogenous antigens, and performing initial optimization protocols (D’Amico, Skarmoutsou, and Stivala 2009;
Greenwell, Foley, and Maronpot 1993).
An AR issue unique to BrdU IHC is the specificity of antiBrdU mAbs for single-stranded DNA. Antibody binding thus
requires a denaturation or degradation step, typically with
hydrochloric acid and/or nuclease digestion. These treatments
can further increase background BrdU staining, alter immunoreactivity to other antigens, and disrupt tissue morphology (Kass
et al. 2000; Dover and Patel 1994; Liboska et al. 2012).
Approaches developed to avoid these issues include use of
sodium hydroxide to relax DNA and monovalent copper ions
to create gaps in DNA (Liboska et al. 2012). EdU, which is a
more recently developed thymidine analog, does not require
this denaturation step and is currently used as a fluorescencebased alternative to BrdU (Mead and Lefebvre 2014).
Quantification of Cell Proliferation Markers
Perhaps the most important source of variation in proliferation LIs is the method used for measuring positively labeled
cells. For example, a recent interlaboratory reproducibility
study of Ki-67 in the same set of human cancer samples
reported mean LIs from 7% to 24% (Polley et al. 2013). This
wide range was attributed to differences in region selection,
cell counting methods, and subjective thresholds for positive
labeling. Other sources of variation include selection criteria
for specific cell types; tissue heterogeneity and staining hot
spots; the number of fields and cells counted; and digital imaging applications (Dowsett et al. 2011). Variability in cell
counting methods can limit comparisons to historical control
values, inter-study and interlaboratory data comparisons of
treatment effects, and use of proliferation LI data for modeling
applications and clinical and safety assessments. Here we will
briefly review basic counting approaches and discuss considerations that may influence data interpretation and improve
standardization.
The simplest way used to quickly assess the number of proliferating cells is by visual estimation. Typically, arbitrary categories for percentage of positive cells are preset (e.g., <10%,
10–25%, 25–50%, 50–100%), and one or more pathologists
blindly grade slides according to these categories. Staining
intensity (e.g., 1þ to 4þ) may be included as an additional
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descriptor. While expedient, this method is more subjective
than individual cell counts and applicable mainly to tumor samples with a much greater range of LIs compared to nonneoplastic tissues, which generally have control LI ranges <10% (and
often <1%). Such low values cannot be reliably categorized by
qualitative evaluation.
The most common method for determining LIs in targeted
toxicological studies is cell counting by light microscopy. An
important recommendation for these studies is to use actual cell
counts for the LI (i.e., positive target cells/total target cells
counted) rather than the positive cells per field or unit tissue
area. Percentage-based LIs provide a standardized end point
and avoid bias resulting from changes in cell or tissue size.
Prior to digital imaging, cells were counted manually in real
time using a click counter; today, counts are typically performed on digital images that can be annotated and saved for
reference (Dölemeyer et al. 2013). As with IHC staining protocols, there are many different techniques used for manual
counts and limited standardization of methods, which are often
tissue-specific and developed empirically within each laboratory. General considerations include field selection, the number
of fields and cells to count, signal thresholds for positive labeling, and whether to focus on a specific tissue compartment,
region, or cell type of interest.
Take, for example, a targeted cell proliferation study in the
liver. The following criteria should be determined prior to counting: number of total cells counted per sample (typically 1,000),
the objective magnification for imaging (20 or 40), and the
number of fields to be counted (typically 3–6 across 2 or 3 different lobes; Ross et al. 2010). Fields are often selected using
random coordinates or arbitrary assignment, excluding areas
with clear artifacts or lesions (e.g., extensive necrosis, inflammation, or neoplasia). Adjacent sections stained with hematoxylin
and eosin (H&E) for histopathology may be helpful for identifying lesions in the area to be counted. Morphological cell selection criteria should also be predetermined to distinguish large
mature hepatocytes from smaller or spindle-shaped cells, which
may or may not represent a hepatocyte lineage or target cell of
interest. Finally, compartmentalization of liver counts into centrilobular, midzonal, and periportal regions may be needed in
some cases to discern a zone-specific effect.
For tissues with potential clustering of proliferative cells,
digital filters may be useful to spread out counts over a larger
area, define regions of interest (ROIs), and reduce the impact of
hot spots. For example, normal intestinal epithelium has a high
background rate of proliferation in the crypt cells but not in
more apical cells. Here it is important to systematically divide
the tissue into crypt and apical compartments and perhaps even
more specific ROIs. For such rapidly proliferating tissues such
as the intestine, morphometric evaluation of crypt size may be a
more sensitive indicator of cell proliferation rather than LI. The
LI may be similar in untreated versus treated intestine, despite
significant expansion of the crypt size and consequently the
number of proliferating cells. Applying digital color thresholds
for positive cells is another important way of increasing consistency and reducing intra- and interobserver variation in cell
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counts. For manual counting, establishing reference images of
borderline weak positive cells prior to data collection are helpful in maintaining these thresholds.
Digital image analysis methods now allow for automated
measurement of LIs (van der Loos et al. 2013). Advantages
of this approach include improved efficiency (e.g., decreased
observer time), objectivity (e.g., for positive cell thresholds),
tissue coverage (e.g., with whole slide analyses), and quantitative analytical capabilities (e.g., target cell/ROI selection).
Automated identification of labeled and unlabeled nuclei is
typically based on thresholding functions that partition a digital
image into elements based on pixel intensity values across different color channels. Optimal thresholds for detection of negative and positive nuclei will vary based on a number of
different pre- and post-processing factors. Thus, analytical programs are generally specific to a particular laboratory, study, or
even batch of IHC slides within a study. For any automated
counting system, it is important that only the target cell type
of interest is actually counted rather than multiple or all cell
types.
Standardization of image capture and processing (e.g., white
balance, contrast) and internal validation of thresholds (e.g.,
using a comparison of manual and automated LIs) should be
addressed on a case-by-case basis. Tissue-specific considerations include the use of cell size and shape thresholds, establishing ROIs (e.g., to exclude non-target cells or compartments), and
splitting of touching nuclei into separate objects (e.g., in colonic
epithelium). As for manual counts, the sampling parameters
should be clearly defined, and inferences should be limited to the
specific cell populations counted. For IHC staining, it is important to optimize counterstaining, since variation here may impact
negative cell counts (e.g., weaker counterstain may inflate LI) or
decrease specificity between labeled and nonlabeled cells. Other
quality control issues relate to management of raw and annotated
digital images as archived data (Dölemeyer et al. 2013), particularly in good laboratory practice (GLP) studies. For example, to
maintain compliance with U.S. Food and Drug Administration
(FDA) electronic record guidelines, software used to generate,
measure, and assess GLP data must have an audit trail and a reliable method of electronic storage (FDA 2003).
In some cases, more sensitive stereological approaches may
be needed to detect subtle changes in LI or density of labeled
cells with greater confidence. Stereology allows reconstruction
of the third dimension within an organ using statistical sampling principles and modeling analyses, which are particularly
useful for specialized structures or cell populations (Falcão
et al. 2013). Proper stereological methods avoid potential
sources of bias inherent to methods using a limited number
of sections (such as lack of uniformity throughout the organ)
and accommodate changes in organ size for cell density estimates. For proliferation studies, stereological methods may
also be used to capture the number of labeled cells at a whole
organ level, expressed as sum totals or density estimates normalized by organ volume. This type of information is important
for treatments that may significantly affect organ volume and/
or total cell number without altering LI. More detailed reviews
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of these approaches are provided elsewhere (Boyce et al.
2010).
CONSIDERATIONS

FOR THE

DESIGN

OF

PROLIFERATION STUDIES

Cell proliferation is a dynamic process influenced by many
factors, including the target tissue and cell type, time course of
exposure, model system, and treatment conditions. Experimental factors such as diurnal variation and whether to fast animals
prior to termination should be addressed, as these can significantly alter the LI of some tissues. Proper understanding of
such factors can be important to the quality of data obtained
from targeted proliferation studies. In this section, we will discuss issues related to study design, focusing on marker selection, temporal dynamics of marker expression, and model
and statistical considerations.
Marker Selection
The most widely used IHC label for proliferation in preclinical in vivo studies is BrdU. Despite being widely considered
as the marker of choice, BrdU is contraindicated in certain tissues and study types. As noted earlier, the major disadvantage
of BrdU for standard applications is the requirement for in-life
labeling either by pulse or continuous exposure. Surgical placement of osmotic pumps can introduce a number of potential
study issues, including loss of animals due to health complications (e.g., anorexia, infections) and potential effects on other
study parameters influenced by anesthesia and surgery near the
time of sacrifice (e.g., hormonal, metabolic, or inflammatory
markers; Wyatt et al. 1995). Decreased feed intake may in turn
affect dosing of the test article if given via the diet. Administration of BrdU can be directly toxic when administered at high
doses or for long durations, or in some cases induce proliferative activity (e.g., in the thymus and adrenal cortex), potentially
confounding experimental results (Nolte et al. 2005). Exposure
of cultured cells to BrdU has also been shown to alter gene
expression, DNA repair, and mutational profiles (Minagawa
et al. 2005; Masterson and O’Dea 2007; Taupin 2007), and thus
BrdU may not be suitable for studies with concurrent genomic
or genetic end points.
Unlike BrdU, Ki-67 and PCNA markers do not require in-life
labeling. This allows for retrospective evaluation of archived
samples (e.g., tumor case series) and eliminates potential inlife marker effects on transcriptomic data. Disadvantages of
PCNA include formalin sensitivity and expression due to functions beyond cell proliferation, including DNA repair and apoptosis (Paunesku et al. 2001). Use of PCNA may thus be
contraindicated for proliferation studies of potential DNAdamaging agents. The longer half-life of PCNA may also mask
a potential treatment effect in tissues with higher background
rates of proliferation by increasing control LIs. Both PCNA and
Ki-67 have discrete windows of expression in the cell cycle and
thus avoid the cumulative labeling of cells seen with BrdU. This
single time point (snap shot) feature may be a disadvantage if
time course dynamics of a potential mitogenic burst effect are
very acute or not known. For example, using a 7-day exposure

8

WOOD ET AL.

time point for a mitogen that caused an acute burst of proliferation at day 3 may lead to a false negative result. In cases when
predicted changes are uncertain, multiple time points are recommended. An additional consideration for Ki-67 is the lag effect
relative to the cell cycle (low G1 and high G2 expression), which
could potentially skew expression lower for agents that arrest
cells in G0/G1 and higher for agents that arrest cells in G2/M
(Scholzen and Gerdes 2000; Dowsett et al. 2011). Other effects
such as loss of histone deacetylation have also been shown to
selectively alter Ki-67 expression during mitosis (Xia et al.
2013). Use of an alternate label is recommended if such
marker-specific effects are suspected. For Ki-67 and other labeling methods, if there is concern about the results (e.g., apparent
lack of increased LI in the presence of obvious cytotoxicity),
complementary assessment of mitotic rate can be helpful.
In-life BrdU Exposure
As described earlier, frequency and duration of BrdU exposure may have an important impact on LI. To account for variation, BrdU protocols should be optimized for the particular
study type and tissue of interest. For rapidly proliferating tissues (e.g., intestinal or lymphoid tissues), a single exposure
to BrdU will result in labeling of sufficient numbers of labeled
cells to detect a treatment effect. These burst protocols are useful for defining the number of S phase cells over a short time
period (6 hr) but do not provide information on kinetics
(e.g., doubling time). Single-dose protocols may also show
high intra- and inter-day variability, which can be minimized
to some extent by standardizing the time of day that samples
are collected.
In tissues with low proliferative activity, BrdU dosing often
needs to be extended to provide an adequate dynamic range of
labeled cells. Such tissues require continuous exposure to BrdU
achieved through the use of osmotic mini-pumps or frequent
dosing. For these studies, a 3- to 7-day exposure typically
results in labeling of sufficient numbers of proliferating cells
within target and control tissues. Continuous exposure protocols provide feedback on the total proliferative activity during
administration but do not distinguish between cells in S phase
and those that have exited S phase during the labeling period.
Compared to pulse-labeling, continuous exposure protocols are
better controlled for intra- and inter-day variability. Since
labeling is a function of BrdU exposure time, LIs from studies
with variable labeling-exposure durations generally should not
be directly compared. If such comparisons are necessary, a
division rate can be used to correct for labeling exposure
(Moolgavkar and Luebeck 1992). In some tissues such as urinary bladder, placement of a subcutaneous mini-pump can produce sufficient stress to alter the LI. Under such circumstances,
pulse-labeling or use of Ki-67 may be preferable (Cohen et al.
2007).
Model Considerations
Model selection should be tailored to the particular goals of
the study. For targeted proliferation studies designed to address
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carcinogenic MOA, the species, strain, and sex should match
that of the bioassay in which the tumor outcome was observed.
In addition, the source of animal, diet, and starting age of the
animals should be matched as much as possible. Similarly, in
investigative studies, the experimental models should match
as closely as possible the life stage and hormonal context of the
human disease being studied. Diet considerations include caloric intake and soy isoflavone exposure from chow-based formulas, which can potentially influence cell proliferation
(Allred et al. 2004). In general, isoflavone-free diets should
be used. Finally, specialized protocols should be consulted
when using proliferation markers in alternative models such
as small fish (Law 2001; Santhakumar et al. 2012).
Tissue-specific Dynamics
Tissues from adult control animals exhibit a wide variation
in normal background rates of cell proliferation, from constant
high LIs (e.g., hematopoietic cells, intestinal epithelial cells,
male germ cells) to low or barely detectable LIs (e.g., cerebrocortical neurons, cardiomyocytes). Given the many variables
that may affect LIs, it is difficult to provide specific background rates of proliferation for most individual tissues or cells.
However, a working knowledge of control LI ranges previously
reported in the literature can help identify variance estimates
for sample size determination and potential technical problems
when they occur. For example, control hepatocyte LIs in a
study of young adult B6C3F1 male mice using osmotic minipumps with 3-day administration are typically <3%; values
much higher than this may be cause to question the validity
of methods or data (e.g., nonspecific staining).
Temporal Dynamics
The time course of a mitogenic or regenerative LI response
is often cell- or tissue-specific. Schematic examples are given
in Figure 2B, which shows hypothetical proliferation LI
curves for an acute burst mitogen (e.g., peroxisome
proliferator-activated receptor a [PPARa] agonist in liver),
a plateau mitogen (e.g., estrogen in endometrial glands), and
a delayed regenerative proliferative response (e.g., chloroform in kidney tubular epithelium). Note that the timing of
initial response and ‘‘decay’’ following an acute burst may
vary by tissue, agent, and dose. Understanding these types
of time course dynamics for the target tissue of interest is
an important element of study design. For example, proliferation studies in the liver often include a 3- to 7-day time point
to detect acute mitogenic effects with a 28-day time point to
confirm reversal of the burst and to detect any delayed regenerative effects (Ross et al. 2010). Data from a single 14-day
time point in between mitogenic and regenerative proliferation windows may be more difficult to interpret. Other tissues
such as lung may also require short <7-day windows for
detection of acute proliferation bursts (Strupp et al. 2012;
Cruzan et al. 2013). For tissues lacking well-established
responses, pilot studies using known positive mitogenic controls may be needed to establish temporal dynamics.
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Dose Considerations
For known tumorigens, a suitable dose range should allow
evaluation of concordance between any effects on proliferation LI and tumorigenic responses in the corresponding carcinogenicity study (e.g., EPA 2005). For proliferation-based
MOAs, concordance would be supported by a proliferative
response at or below the tumorigenic dose level. In contrast,
a single-dose proliferation study at an exposure above the carcinogenic dose would not be considered adequate. If available, results of other toxicity studies on the agent of interest
should be reviewed to avoid systemic toxicity or overt cytotoxic effects in the target tissue. As noted elsewhere, cytotoxicity with regenerative proliferation may potentially mask a
direct mitogenic effect and increase variability in LI data
(Wood et al. 2014).
Tissue Compartmentalization
Measurement of LIs should be restricted to target compartments and cell types of interest within a given tissue type. In
many cases, these compartments or cell types can be reliably
identified by morphology (e.g., mammary gland lobular and
ductal epithelium). However, different protocols and/or studies
may still be required to accurately assess LIs across cell types.
For example, within the kidney, proliferation LI responses vary
between glomeruli and tubules and between proximal and distal tubules (Umemura et al. 2004). If the proximal tubules are
targeted, a 3-day BrdU labeling-exposure would be adequate
based on proliferation rates of the epithelium. If the collecting
ducts are targeted, the labeling-exposure should be longer (>7
days; Nolte et al. 2005).
For counting, it is often challenging to obtain LIs for cell
types that are difficult to identify histologically. Examples
include C-cells in the thyroid gland, endothelial cells in liver
or adipose tissue, and smaller non-hepatocyte cell populations
in the liver (Nolte et al. 2005; Ohnishi et al. 2007). In such
cases, a double-labeling IHC approach may be required using
a proliferation label in combination with a cell-specific marker (e.g., calcitonin for C-cells, CD31 for endothelial cells,
and CD68 for Kupffer cells). This type of approach may also
be helpful in mechanistic studies for relating proliferative
responses to upstream molecular events (e.g., receptor expression). Without a double label, it is important to clearly specify
what visual or computer-assisted cell selection criteria were
used to identify target cells of interest.
Other Statistical Considerations
As with other end points, sample size and effect variance
will determine the statistical power of LI results. Expected
treatment effect (change versus control) as well as control LIs
will inform the number of samples and cells to count per sample (Morris 1993). Sample size is the primary driver for power,
so power decreases as sample size is reduced, even if more cells
are counted per sample. In general, for a given fold-change in
LI from control, larger sample sizes are needed to meet power

FIGURE 3.—Distribution and range of proliferation labeling index (LI)
data in different tissue types. (A) Ki-67 labeling in hepatocytes showing lower LI control and response values and larger sample size (n ¼
10/group). (B) Ki-67 labeling in uterine glands showing higher LI values and response range and lower sample size (n ¼ 5–6/group). con ¼
control; d1–d3 ¼ dose groups; t1–t3 ¼ treatment groups. *p < .05
compared to control group.

thresholds when the control LIs are lower. Similarly, treatmentinduced changes will be harder to detect when LIs are lower,
and thus more cells per sample should be counted to reduce
variance and increase power in this case (Morris 1993). In a
simple example provided by Morris (1993), a 2-fold increase
in LI when the control value is near 5% was comparable in
power to a 3.5-fold increase in LI when the control value was
near 1%.
These concepts are illustrated in the Ki-67 LI data sets
shown in Figure 3. Note that labeling data in both sets are
asymmetrically distributed (clumped toward zero) with nonhomogeneous variance across groups. Analysis of group differences thus require nonparametric analysis, which is typical
for LI data. This skew does not strongly influence power outcomes, which can be calculated using either a t-test or a rank
sum test (Morris 1993). For the low-LI study (Figure 3A), the
population mean and standard deviation were estimated at
1.5% and 1.4%, respectively, and the expected treatment effect
was a 2-fold increase in LI. The sample size in each group providing an 80% chance at a .05 significance level to detect a statistically significant difference was 10 after adjusting for
multiple comparisons. For the high-LI study (Figure 3B), the
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population mean and standard deviation were estimated at 9%
and 14%, respectively, and the expected treatment effect was a
3.5-fold increase. Here, the sample size in each group required
for 80% power was only 5. These data sets highlight the importance of using either historical or pilot data of the target cell
population to assess both variance and range of LIs. When presenting LI data, it is recommended that actual means are given
with standard deviation or standard error values rather than
simple fold-change values from control (especially when LIs
are low). As described earlier, presenting only the total positive
cells per field (rather than LI) is not sufficient for standard analyses, since this metric may be biased by shifts in the total number of cells/nuclei present in each field.
Complementary Markers
As with other potential treatment effects, cell proliferation
data should be considered in context of other information about
a given compound. Relevant effects may include gross and histopathological lesions (e.g., necrosis) and changes in organ
weights, circulating hormones, gene expression markers, and
biochemical or cell-based data. This information may help
identify early molecular events associated with a proliferative
signal, distinguish a risk signal from an expected pharmacologic response, and aid in the interpretation of marginal or equivocal treatment effects on LI.
One of the most common processes evaluated alongside cell
proliferation is apoptotic cell death. Apoptosis plays a central
role in organ homeostasis, and imbalance between apoptosis
and cell proliferation has an established role in tumorigenesis
(McDonnell 1993; Elmore 2007). Many different techniques
are currently used to detect or measure apoptosis. These include
evaluation of cellular morphology, either by light or electron
microscopy; markers of DNA fragmentation (e.g., terminal
deoxynucleotidyl transferase 20 -deoxyuridine, 50 -triphosphate
nick end labeling [TUNEL]) and repair (e.g., poly-adenosine
diphosphate-ribose polymerase); plasma membrane changes
(e.g., annexin V); and expression of proteins directly involved
in apoptotic pathways (e.g., caspases, Bcl-2, Bax, p53; Elmore
2007). While morphologic evaluations can be used for qualitative identification of apoptotic cells, these molecular indicators
of apoptosis are generally required to demonstrate quantitative
dose-related changes.
The most widely used IHC marker in toxicological evaluations for in situ measurement of apoptosis LI is TUNEL, which
labels 30 hydroxyl ends of fragmented chromatin from cells in
the late stages of apoptosis (Negoescu et al. 1996). Due in part
to off-target TUNEL staining in necrotic cells (due to endogenous endonuclease activity), the use of cleaved caspase 3 (CC3)
has gained in popularity as a more specific IHC label for apoptotic cells (Gown and Willingham 2002). Assays for both
TUNEL and CC3 IHC are applicable to standard FFPE tissues,
and positively labeled cells are typically discrete and readily
quantified.
Many of the pre-analytical and cell counting issues for measuring apoptosis LIs are similar to those described earlier for
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cell proliferation. Here, we will only highlight a few considerations that relate more specifically to the use of apoptosis LI
data. Probably the most important issue related to cancer
assessment is the fact that for certain tumorigenic agents the
effect in question is apoptosis inhibition rather than induction.
A classic example is 2,3,7,8-tetrachlorodibenzo-p-dioxin,
which inhibits apoptosis and alters proliferation in the liver via
activation of the aryl hydrocarbon receptor (AhR) pathway
(Budinsky et al. 2014). The challenge here is that basal apoptosis indices are very low in many adult (nonlymphoid) tissue
types (often <0.1%), making it unfeasible in many cases to
show a statistically significant decrease in LI in normal cells.
In some cases, an inhibitory effect on apoptosis LI may only
be observable in specific cell populations such as preneoplastic
hepatic foci (Stinchcombe et al. 1995; Budinsky et al. 2014).
Given these low LIs, it is often necessary to count more cells
for apoptosis compared to proliferation markers. Other potential issues related to apoptotic cell LIs, particularly with
TUNEL, include cross-reactivity with cells undergoing necrosis or DNA repair, fixation and pretreatment effects on detection of DNA strand breaks, and sensitivity and specificity of
the end-labeling technique.
CURRENT APPLICATIONS

OF

CELL PROLIFERATION DATA

Cell proliferation data are most commonly used in cancer
risk assessment to evaluate the MOA for a specific tumor outcome observed in a rodent carcinogenicity study (Boobis et al.
2006; EPA 2005). Establishing the key events in an MOA
allows for assessment of human health relevance, dose–
response extrapolation, and identification of potential susceptible populations (EPA 2005). Weight-of-evidence evaluations
of key events in a putative MOA include strength, consistency,
and specificity of effects; dose–response and temporal relationships; biological plausibility and coherence; and alternative
MOAs (Sonich-Mullin et al. 2001; Boobis et al. 2006). Kinetic
and dynamic factors and no observed adverse effect levels
(NOAELs) are also used to evaluate the plausibility of tumorigenic effects relative to potential human exposure and whether
or not the MOA events are rodent-specific (Boobis et al. 2006;
Cohen et al. 1991, 2004; Cohen and Ellwein 1990).
Traditional MOAs for carcinogenicity can be broadly divided
into mutagenic and non-mutagenic categories (Weisburger and
Williams 1981; Cohen and Ellwein 1990; Boobis et al. 2006;
Preston 2013). Mutagenic MOAs operate through DNA damage
(as a primary event), while non-mutagenic MOAs occur most
commonly via mitogenesis or cytotoxicity-induced cell proliferation. Select examples of established non-mutagenic MOAs
are listed in Table 2. Resistance to apoptosis is a hallmark of cancer cited in some MOAs as an ancillary event, but few published
MOAs appear to act solely through this mechanism (i.e., without
concomitant effects on proliferation).
To examine the role of quantitative proliferation data in cancer MOA evaluation, a survey was recently conducted of pesticides previously assessed by the U.S. Environmental
Protection Agency (EPA; Lake et al. 2014). The most common
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TABLE 2.—Select examples of non-genotoxic modes of action for rodent tumor outcomes mediated by either mitogenic or regenerative
proliferation.
Organ: cell target

Early key event/events

Index agent

Reference

Mitogenic proliferation
Liver: Hepatocyte
Lung: Bronchiolar ept
Testes: Leydig cells
Thyroid: Follicular ept

Receptor activation > CYP induction
Club cell metabolism
HPG disruption > Increased LH
HPT disruption > Increased TSH

Phenobarbital
Isoniazid
Flutamide
Thiazopyr

Elcombe et al. (2014)
IARC (1987)
Cook et al. (1999)
Dellarco et al. (2006)

Regenerative proliferation
Liver: Hepatocyte
Kidney: Tubular ept
Nasal cavity: Squamous ept
Urinary bladder: Urothelial ept

Sustained cytotoxicity > Liver cell necrosis
CYP2E1 metabolism > Tubular cell necrosis
Sustained cell death
Calculi > Urothelial cell death

Thiamethoxam
Chloroform
Acetochlor
Sodium saccharin

Pastoor et al. (2005)
Golden et al. (1997)
Genter et al. (2000)
Cohen et al. (1991)

Note: CYP ¼ cytochrome P450; ept ¼ epithelium; HPG ¼ hypothalamic pituitary gonadal; LH ¼ luteinizing hormone; TSH ¼ thyroid-stimulating hormone.

tumor site for proposed MOAs was liver. Of the 21 compounds
with liver tumor MOAs, 16 had MOAs accepted by the EPA
using current guidelines (EPA 2005). Mitogenic MOAs were
predominant, and a significant increase in proliferation as measured by BrdU, Ki-67, or PCNA LI was observed at 7 days for
all but one of these compounds with accepted MOAs. In contrast, short-term effects on proliferation LI were inconclusive
or not provided for all unaccepted MOAs. Notably, the percentage of rodent liver tumorigens classified as likely human carcinogens was markedly lower among compounds with an accepted
liver tumor MOA compared to those without an accepted MOA.
Proper demonstration of tumorigenic MOAs, and exclusion
of alternative MOAs, includes quantitative cell proliferation
data in most cases in which there is not a clear diagnosis of
hyperplasia on histopathology. For non-genotoxic carcinogens,
tumors occur at detectable incidences at the same, and often
only at higher, doses than early key events such as proliferation. Establishing the lowest effect levels for these events thus
provides a rationale for a biological threshold underlying a particular tumor outcome and a basis for the reference dose or concentration. Even for tumorigens with evidence of genotoxicity,
proliferation data may be needed to evaluate alternative nongenotoxic MOAs (Cohen and Ellwein 1990). Following are 2
case examples illustrating how proliferation data have been
used to assess MOAs and evaluate human relevance of tumor
outcomes in rodent carcinogenicity studies.
Mitogenesis
Mitogenic carcinogens typically operate through hormonal or
growth factor receptors. Examples of hormonal mitogens
include estrogens in the uterus, thyroid-stimulating hormone
(TSH) in thyroid follicular cells, and gonadotropins in the
gonads. Nonhormonal mitogens include various endogenous
growth factors (e.g., epidermal growth factor, tumor necrosis
factor a) and xenobiotic agents that activate receptors such as
constitutive androstane receptor (CAR) and PPARs, most prominently in the liver (Holsapple et al. 2006). Disruption of endocrine axes may also lead indirectly to mitogenesis. Common
examples here include xenobiotic-induced liver metabolism of

thyroid hormones leading to increased TSH and secondary thyrotropism and alteration of the hypothalamic–pituitary–gonadal
axis leading to increased luteinizing hormone (LH) release and
interstitial cell hyperplasia and neoplasia in the testes.
One of the most widely studied mitogenic rodent carcinogens is phenobarbital (PB), which was identified decades ago
as a liver tumor promoter in mice (Elcombe et al. 2014). Activation of CAR has been shown to be the initiating requisite
event in the tumorigenic MOA for PB, followed by increased
hepatocyte proliferation, preneoplastic foci, and tumors (Holsapple et al. 2006; Elcombe et al. 2014). Pregnane X receptor
(PXR) activation, cytochrome P450 enzyme induction, hepatocellular hypertrophy, and increased liver weight are considered
to be associative events for CAR activation but not necessarily
requisite key events (Elcombe et al. 2014).
Historically, PB has been an important reference agent in
establishing the concept that some rodent tumor outcomes have
low human health relevance (Elcombe et al. 2014). Epidemiologic data based on decades of PB use as a human pharmaceutical showed no evidence of increased liver tumor risk (IARC
2001), and experimental studies in mice lacking CAR and PXR
did not exhibit hypertrophic or proliferative responses to PB
(Ross et al. 2010). While the human liver expresses CAR and
PXR, receptor activity is markedly lower than in rodents. These
findings were supported by studies in mice expressing human
CAR/PXR, which showed increased liver weight and enzyme
induction without liver cell proliferation (as measured by
BrdU LI) in response to PB (Ross et al. 2010). A more recent
study further demonstrated that PB-related metabolic effects
occurred in human cells in a chimeric mouse model, but without the proliferative effect (Yamada et al. 2014). This lack of
proliferation in humanized models helped demonstrate the concepts that increased proliferation is an essential thresholdbased event for mitogenic tumorigens and that early key events
can be used to evaluate human relevance.
Cytotoxicity
The other major category for non-genotoxic tumorigens is
chronic cytotoxicity. Key events in this MOA include necrosis
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(in rare cases apoptosis) with consequent growth factor signals
leading to regenerative cell proliferation. This process is frequently, but not always, associated with inflammation, depending on the extent of the tissue damage. A classic case study of
this MOA is sodium saccharin, which was shown in early carcinogenicity studies to induce urinary bladder tumors in rats.
Mechanistic studies indicated that these tumors were associated with calcium phosphate-containing microcrystals that
formed when high oral consumption of sodium saccharin produced a highly osmolar alkaline environment with high calcium and phosphate and urinary pH >6.5 (specific to the rat;
Cohen et al. 1991; IARC 1999a). The crystals induce damage
of the superficial urinary bladder epithelial cells leading to
chronic regenerative cell proliferation and eventually tumors.
Treatments that acidify urine inhibit the crystal formation,
urothelial toxicity, cell proliferation, and tumor formation (Ellwein and Cohen 1990; IARC 1999a, 1999b). Crystal formation
and bladder epithelial proliferation were not observed in studies of mice or nonhuman primates (Takayama et al. 1998), and
no clear evidence of bladder carcinogenicity was demonstrated
in human epidemiologic studies (Weihrauch and Diehl 2004;
IARC 1999b; Elcock and Morgan 1993). As with the mitogenic
example for PB, the tumorigenic effects of sodium saccharin
were contingent upon the increase in urothelial cell proliferation observed specifically in rats (Ellwein and Cohen 1990).
FUTURE APPLICATIONS

OF

CELL PROLIFERATION DATA

One of the primary goals of predictive toxicology is to
facilitate a transition in safety assessment from traditional histopathology outcomes to more expedient toxicity pathwaybased end points (Thomas et al. 2013). The scope of the MOA
framework has recently been expanded to incorporate this type
of approach and the broad range of data types required (Meek
et al. 2014). These ideas have also been integrated recently into
the adverse outcome pathway (AOP) construct, which is conceptually similar to an MOA but designed for more prospective
or predictive applications (Ankley et al. 2010; OECD 2012). A
primary aim of the modified MOA and AOP frameworks is to
integrate quantitative data into models that link early events
with more chronic health outcomes using probabilistic relationships (Simon et al. 2014). In the future, it is expected that these
pathway-based models will have an increasingly prominent
role in hazard identification, chemical prioritization for testing,
and safety assessment (Thomas et al. 2013).
For cancer risk assessment, this ‘‘reverse engineering’’
approach would involve initial evaluation of more chemicals
or drugs in the absence of 2-year rodent bioassay data. Current
prospective risk models for cancer can be broadly divided into
negative predictive and prioritization categories. The ultimate
goal of negative predictive cancer models is not to predict specific tumor outcomes in rodents but to use short-term data to
determine whether oncogenicity studies would likely be negative or of little value to human health risk assessment (Sistare
et al. 2011; Reddy et al. 2010; Cohen 2004, 2010; Boobis
et al. 2006; Meek et al. 2014). This type of evaluation would
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incorporate various data types, including pharmacological
activity, genotoxicity, hormonal effects, subacute histopathological effects, and, in some cases, targeted assays related to cell
proliferation (Cohen 2004; Morton, Bourcier, and Alden 2013).
A formal strategy based on this concept was submitted in
2013 as a proposal to change the current International Conference on Harmonization S1 guidance on rodent carcinogenicity
testing of pharmaceuticals (FDA 2013). Under the proposed
changes, data from non-carcinogenicity studies would be submitted as part of a Cancer Assessment Document (CAD) that
would justify whether or not a 2-year rat bioassay would affect
the overall human cancer risk assessment of a compound. As
outlined, these CADs may include specific mechanistic targets
as well as data from emerging technologies and alternative test
systems (FDA 2013). This evidence would then be used to
explain or predict potential carcinogenic pathways affected
by the compound and characterize their potential relevance to
human cancer risk. In this negative predictive setting, the main
uses of proliferation data would be to clarify a potential risk
signal (e.g., increased organ weight) or support an MOA of low
concern for human cancer risk.
The second modeling strategy applies mainly to environmental chemicals with limited safety data. In this approach,
high-throughput screening assays and other short-term models
would be used to identify early molecular events potentially
associated with cancer risk. Initial data may come from in vitro
assays for nuclear receptor or growth factor receptor activity,
structure–activity relationships, in silico and tissue culture
models, acute in vivo transcriptomic profiles, and other systems
designed to profile large numbers of compounds in a short
period of time. This information would be used to categorize
biological activity, pathway targets, and dose potency in reference to known tumorigens and non-tumorigens, and computational models would be applied to identify risk signals and
inform which compounds require additional testing (Kleinstreuer et al. 2013; Meek et al. 2014; Thomas et al. 2013;
Gusenleitner et al. 2014). While not clearly defined, shortterm proliferation LI data in this prioritization setting would
likely serve as a second-tier functional end point to evaluate
a potential risk signal (e.g., receptor activation) and establish
a dose response. An initial evaluation of human relevance
could then be conducted based on the presence or absence of
these earlier key events.
A central premise for these prospective strategies is that protecting against requisite early key events in carcinogenesis will
protect against the tumor outcome itself. Consider, for example, an agent that has structural alerts and transcriptomic signals for thyroid activity. A short-term rat study shows
increased hypertrophy and proliferation LI of follicular epithelial cells, and follow-up evidence indicates inhibition of iodide
pump activity, decreased thyroid hormone synthesis, and
increased TSH release from the pituitary gland. If no genotoxicity concerns are present, then reference dose estimates would
likely be based on these short-term thyroid effects, regardless
of whether a thyroid tumor outcome was later observed in a
2-year rat carcinogenicity study. A similar scenario could be
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constructed for other rodent tumor outcomes with established
MOAs/AOPs. In many of these cases, proliferation LIs could
serve as the functional end point for dose response estimates,
as in traditional MOA evaluations.
There are a number of important issues that need to be
addressed to increase the usefulness of these prospective
models (Tice et al. 2013). Perhaps the most critical challenge
is establishing when an early molecular signal is specific to an
adverse biological effect (Simon et al. 2014). For proliferation, many screening assay or genomic signals may not necessarily lead to increased LI, and many responses in LI may not
necessarily lead to cancer. Proliferation by itself does not
imply carcinogenesis risk and in many cases may represent
an expected physiologic or therapeutic response for some targeted pharmaceuticals (e.g., induction of erythroid hyperplasia in bone marrow by erythropoietin-stimulating therapies
for anemia). Future models of cancer risk assessment will
need to reconcile this balanced accuracy issue, providing adequate sensitivity while still discriminating adverse signals
from incidental or adaptive ones. In the near term at least, this
will require better integration of data from higher throughput
systems, short-term functional end points like proliferation,
and traditional morphologic outcomes.
SUMMARY

AND

CONCLUSIONS

Cell proliferation data play an important role in the evaluation of tumor outcomes observed in carcinogenicity studies.
This application is based on extensive evidence indicating that
increased proliferation LIs represent a necessary precursor
event for most non-genotoxic carcinogens. Dose thresholds
based on LIs (or associated changes) thus provide a way to
assess and protect against cancer risk from chemical exposures.
The proper interpretation of LI data and use in risk assessment
requires an understanding of the different markers, technical
variables, and analytical methods. In this article, we have
reviewed many of these issues and highlighted considerations
for better design of targeted proliferation studies.
As toxicological science moves to more predictive
approaches, new roles will emerge for proliferation data as
short-term quantitative and functional end points. Future modeling work in this area will enable more accurate risk predictions of carcinogenicity based on short-term bioactivity
profiles and better define conditions in which rodent carcinogenicity studies add value to human cancer risk assessment.
These efforts should benefit from improved standardization
of proliferation LI methods across laboratories, more efficient
tools for measuring proliferation LIs, and more explicit criteria
for discerning true positive risk signals.
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